title: Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content.
abstract: Insulin resistance is associated with increased circulating lipids and skeletal muscle lipid content. Chronic nicotinic acid (NA) treatment reduces insulin sensitivity and provides a model of insulin resistance. We hypothesized that the reduction in insulin sensitivity occurs via elevation of circulating nonesterified fatty acids (NEFAs) and an increase in intramyocellular lipid (IMCL). A total of 15 nondiabetic males (mean age 27.4 +/- 1.6 years) were treated with NA (500 mg daily for 1 week, 1 g daily for 1 week). Insulin sensitivity (glucose infusion rate [GIR]) was determined pre- and post-NA by euglycemic-hyperinsulinemic clamp. Substrate oxidation was determined by indirect calorimetry. Skeletal muscle lipid was assessed by estimation of long-chain acyl-CoA (LCACoA) and triglyceride (TG) content and by (1)H-magnetic resonance spectroscopy quantification of IMCL (n = 11). NA reduced GIR (P =.03) and nonoxidative glucose disposal (P <.01) and increased fasting NEFAs (P =.01). The decrease in GIR related significantly to the increase in fasting NEFAs (r(2) =.30, P =.03). The intrasubject increase in basal and clamp fat oxidation correlated with the decrease in GIR (r(2) =.45, P <.01 and r(2) =.63, P <.01). There were no significant changes in muscle LCACoA, TG, or IMCL content. Therefore, induction of insulin resistance by NA occurs with increased availability of circulating fatty acids to muscle rather than with increased muscle lipid content.
authors.affiliation: Garvan Institute of Medical Research, Sydney, Australia.
authors.forename: Ann M
authors.initials: AM
authors.lastname: Poynten
authors.forename: Seng Khee
authors.initials: SK
authors.lastname: Gan
authors.forename: Adamandia D
authors.initials: AD
authors.lastname: Kriketos
authors.forename: Anthony
authors.initials: A
authors.lastname: O'Sullivan
authors.forename: John J
authors.initials: JJ
authors.lastname: Kelly
authors.forename: Bronwyn A
authors.initials: BA
authors.lastname: Ellis
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Chisholm
authors.forename: Lesley V
authors.initials: LV
authors.lastname: Campbell
mesh_terms: D000328:Adult; D002153:Calorimetry, Indirect; D004040:Dietary Carbohydrates / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism*; D005215:Fasting / Q000097:blood; D005227:Fatty Acids / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology*; D050356:Lipid Metabolism; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D009525:Niacin / Q000494:pharmacology*; D010084:Oxidation-Reduction
chemical_list: D004040:Dietary Carbohydrates; D004041:Dietary Fats; D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D009525:Niacin; D005947:Glucose